BIRC5 was identified as a risk factor that promotes lung cancer progression, particularly in patients with Pathologic T2 stage, N0 stage, M0 stage, and residual tumor status (R0), as well as in patients of all age groups (Figures 8E–J). This evidence concerns the gene BIRC5 and neoplasm.